ArticleFrontiers in psychiatry2025
Identification of key genes and pathways in schizophrenia: a bioinformatics analysis based on GWAS and GEO.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular Signatures of Early-Onset Bipolar Disorder and Schizophrenia: Transcriptomic and Machine-Learning Insights into Calcium and cAMP Signaling, Including Sex-Specific Patterns.International journal of molecular sciences · 2025Article
- The Inflammatory Nexus: Unraveling Shared Pathways and Promising Treatments in Alzheimer's Disease and Schizophrenia.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Schizophrenia is a mental illness that is associated with many disorders, such as incoherence of mental activities, and impairment of perception, thinking, emotions, and behavior. Although the exact cause of schizophrenia is unknown, many studies have highlighted the role of genetic background and environmental factors in this disease. Therefore, the identification of key genes involved in schizophrenia provides a promising opportunity to develop novel diagnosis and/or treatment methods. This study aims to investigate schizophrenia-related hub genes by bioinformatics analysis based on genome-wide association (GWAS) and gene expression omnibus (GEO) datasets. Material and methods: In this study, the GWAS catalog and GEO dataset were used to identify key candidate genes and pathways that are important in the diagnosis and treatment of schizophrenia, and then the results were analyzed using Enrichr and Cytoscape tools. Result: According to our result NRXN, CACNA1C, and GRIN2A genes had the highest scores in the GWAS analyses and BRCA1, ATM, and STAT1 genes had the highest scores in the GEO dataset. Also, glucuronidation, ascorbate, and aldarate metabolism pathways in the GWAS, PI3K/AKT and Rap1 signaling in the GEO had the highest associations with schizophrenia. Conclusion: This study highlights the need for further validation of the genes and molecular pathways in schizophrenia. Also, the identified genes could be promising candidates for future diagnostic and/or treatment strategies for schizophrenia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.